海创药业：2025年半年度净利润约-6185万元

Core Viewpoint - Haichuang Pharmaceutical reported a significant increase in revenue for the first half of 2025, with a year-on-year growth of 11,899.08% [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 13.17 million yuan, compared to about 110,000 yuan in the same period of 2024 [2] - The net loss attributable to shareholders for the first half of 2025 was approximately 61.85 million yuan, an increase from a net loss of about 100 million yuan in the first half of 2024 [2] - Basic earnings per share for the first half of 2025 was a loss of 0.62 yuan, compared to a loss of 1.01 yuan in the same period of 2024 [2]